Kemotuss Oral Suspension contains Levocloperastine at a concentration of 20 mg per 5 ml and is indicated for the symptomatic relief of dry cough associated with upper respiratory tract infections and other non-productive cough conditions. Levocloperastine is a non-opioid antitussive agent that acts centrally by suppressing the cough reflex without causing sedation or respiratory depression, making it suitable for use in both adults and children. The suspension formulation allows for accurate dosing and ease of administration, particularly in pediatric patients. Kemotuss Oral Suspension exhibits a favorable safety profile, with minimal adverse effects reported, primarily limited to mild gastrointestinal discomfort or allergic reactions in rare cases. It is contraindicated in patients with known hypersensitivity to Levocloperastine or any excipients present in the formulation. Caution is advised when administering to patients with hepatic or renal impairment, and it should not be combined with other central nervous system depressants without medical supervision. The recommended dosage should be strictly adhered to, and treatment duration should be limited to the shortest period necessary to control symptoms. As with all medications, consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and to avoid potential drug interactions.